Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis
ConclusionWe confirmed MOV as an extremely safe treatment in a large real world population of advanced NSCLC with an interesting activity mainly consisting of long-term disease stabilization. We speculate the possibility of a synergistic effect with subsequent immunotherapy.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Toxicology